AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$RVPH

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Price · $RVPHvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $RVPH in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $RVPH in the last 30 days.

Top stories · $RVPHMore →
MAY 13·Stock TitanMed

Brilaroxazine patent filing may extend to 2046 as Reviva moves from Nasdaq to OTCQB

Reviva (RVPH) reported a reduced net loss of $3.2 million in Q1 2026, alongside an increase in cash to $22.2 million after a $10.0 million equity offering. The company filed a provisional patent for a new form of brilaroxazine, potentially extending its exclusivity until 2046, and anticipates FDA feedback and the start of RECOVER-2 Phase 3 trial enrollment in mid-2026 and Q3 2026, respectively. Reviva's common stock will transition from Nasdaq to the OTCQB Venture Market on May 14, 2026.

APR 23·GlobeNewswire

Reviva to Participate in a Fireside Chat Hosted by A.G.P.

Reviva Pharmaceuticals announced that its Founder, President, and CEO, Laxminarayan Bhat, PhD, will participate in a fireside chat hosted by A.G.P. Equity Research Analyst James Molloy on April 27, 2026. The discussion will focus on recent developments and upcoming milestones for brilaroxazine, a clinical-stage drug candidate with potential across multiple neuropsychiatric and inflammatory indications. Brilaroxazine recently showed positive Phase 3 results for schizophrenia and has received Orphan Drug Designation for PAH and IPF.

DEC 29·GlobeNewswire

Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum

Reviva Pharmaceuticals Holdings, Inc. announced that its Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will present at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026. The presentation will cover the company's work in developing therapies for central nervous system, inflammatory, and cardiometabolic diseases. Reviva is a late-stage biopharmaceutical company with two in-house discovered drug candidates, brilaroxazine and RP1208, in its pipeline.

News on $RVPH

All news →